Skip to content

In the BioHarmony Drug Report Database

Carmustine

Bicnu, Gliadel (carmustine) is a small molecule pharmaceutical. Carmustine was first approved as Bicnu on 1982-01-01. It is used to treat brain neoplasms, carcinoma, colonic neoplasms, ependymoma, and glioblastoma amongst others in the USA. It has been approved in Europe to treat hodgkin disease and non-hodgkin lymphoma. The pharmaceutical is active against glutathione reductase, mitochondrial.
Trade Name Bicnu, Gliadel
Common Name Carmustine
Indication brain neoplasms, carcinoma, colonic neoplasms, ependymoma, glioblastoma, hodgkin disease, lung neoplasms, medulloblastoma, melanoma, multiple myeloma, non-hodgkin lymphoma
Drug Class Antineoplastics (chloroethylamine derivatives)
Carmustine
Get full access now